BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 991 filers reported holding BAXTER INTL INC in Q3 2022. The put-call ratio across all filers is 1.55 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $602,000 | -30.2% | 11,185 | -16.8% | 0.09% | -13.7% |
| Q2 2022 | $863,000 | -17.2% | 13,438 | 0.0% | 0.10% | -1.9% |
| Q1 2022 | $1,042,000 | -0.8% | 13,438 | +9.9% | 0.10% | +25.3% |
| Q4 2021 | $1,050,000 | +3.0% | 12,227 | -3.5% | 0.08% | -4.6% |
| Q3 2021 | $1,019,000 | -0.1% | 12,668 | 0.0% | 0.09% | +4.8% |
| Q2 2021 | $1,020,000 | -9.8% | 12,668 | -5.5% | 0.08% | -13.5% |
| Q1 2021 | $1,131,000 | +5.1% | 13,412 | 0.0% | 0.10% | -11.9% |
| Q4 2020 | $1,076,000 | -3.5% | 13,412 | -3.2% | 0.11% | -9.2% |
| Q3 2020 | $1,115,000 | -65.8% | 13,861 | -63.4% | 0.12% | -33.7% |
| Q2 2020 | $3,265,000 | +0.2% | 37,918 | -5.6% | 0.18% | -11.3% |
| Q1 2020 | $3,260,000 | -4.0% | 40,147 | -1.2% | 0.20% | +22.9% |
| Q4 2019 | $3,396,000 | -5.7% | 40,618 | -1.3% | 0.17% | -13.1% |
| Q3 2019 | $3,600,000 | +6.8% | 41,157 | 0.0% | 0.19% | +7.3% |
| Q2 2019 | $3,371,000 | -1.4% | 41,157 | -2.1% | 0.18% | +3.5% |
| Q1 2019 | $3,420,000 | +23.6% | 42,059 | 0.0% | 0.17% | +6.2% |
| Q4 2018 | $2,768,000 | -14.6% | 42,059 | 0.0% | 0.16% | -1.2% |
| Q3 2018 | $3,242,000 | +4.4% | 42,059 | 0.0% | 0.16% | -3.0% |
| Q2 2018 | $3,106,000 | +16.2% | 42,059 | +2.3% | 0.17% | +14.2% |
| Q1 2018 | $2,673,000 | -1.3% | 41,098 | -1.9% | 0.15% | -1.3% |
| Q4 2017 | $2,708,000 | – | 41,899 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |